Introduction
Transforming growth factor-b1 (TGF-b1) is a 25-kDa homodimeric protein, which regulates a variety of cellular responses, such as proliferation, differentiation, migration and apoptosis (Massague, 1990; Heldin et al., 1997) . TGF-b1 signal is transduced from plasma membrane to the nucleus via serine/threonine kinase receptor type I (TbR-I) and type II (TbR-II). In canonical Smad-dependent pathway, heterodimerization of TbR-II and TbR-I provokes the phosphorylation of Smad2 and Smad3, nuclear translocation of the Smads being complexed with Smad4, and eventual transcriptional regulation of target genes (Shi and Massague, 2003) . TGF-b1 signal is also transduced via Smadindependent pathways through activation of mitogenactivated protein kinase (MAPK), nuclear factor-kB (NF-kB) and phosphoinositide-3-kinase (PI3K-Akt; Derynck and Zhang, 2003) .
TGF-b1 functions as a growth inhibitor in normal cells of the epithelial lineage, and the TGF-b1 signaling pathway is disrupted in a number of human cancer cells by mutational alterations of TbR-I and TbR-II, or Smads. In the prostate, TGF-b1 inhibits growth of carcinoma and normal epithelial cells, and aberrant function of TbR-I and TbR-II correlates with tumor aggressiveness (Kim et al., 1996; Williams et al., 1996) . However, both intracellular and serum TGF-b1 levels are elevated in cancer patients and further increased in patients with metastatic carcinoma (Truong et al., 1993) . Several studies have shown that prostate cancer cells are resistant to TGF-b1-induced growth inhibition, and TGF-b1 actually promotes tumor growth, migration and metastasis, indicating that TGF-b1 action is oncogenically conversed in the process of tumorigenesis (Stearns et al., 1999; Zhu and Kyprianou, 2005; Lu et al., 2007; Pu et al., 2009) . We reported that TGF-b1 promotes cellular proliferation of prostate carcinomas through the activation of Ras/MAPK signaling and induction of tumor-promoting genes, such as interleukin-6, indicating that prostate cancers have a selective growth advantage by autocrine TGF-b1 production (Park et al., 2000 (Park et al., , 2003 .
Vascular endothelial growth factor (VEGF) is a 45-kDa heparin-binding homodimeric glycoprotein with a strong proangiogenic activity (Ferrara, 2004) . VEGF exists as five alternatively spliced isoforms (VEGF 121 , VEGF 145, VEGF 165, VEGF 189 and VEGF 209 ), and VEGF 121 and VEGF 165 are most physiologically relevant in human cells. VEGF transcription is strongly activated by hypoxic conditions, and a variety of transcriptional factors such as AP-1, AP-2 and Sp1 have been known to modulate VEGF expression (Mukhopadhyay et al., 1995; Ferrara, 2004; Loureiro and D'Amore, 2005) . Expression levels of VEGF and its receptors are increased in prostate cancer cells compared with normal prostate epithelial cells, and elevated VEGF is implicated in angiogenic and non-angiogenic events, which are associated with tumor progression, including early tumor spread (Jackson et al., 2002; Pallares et al., 2006) . TGF-b1 has an important role in angiogenesis, and one of the tumor-promoting functions of TGF-b1 is associated with its ability to induce VEGF (Benckert et al., 2003; Sugano et al., 2003; Wang et al., 2004; Jeon et al., 2007) . Recently, it was reported that TGF-b1 activates cell migration and invasion by coordinated induction of VEGF receptor type 3 and matrix metalloproteinase-2/9 in intermediary basal epithelial cells of the prostate, suggesting that TGF-b1 is involved in phenotype changes associated with transitions to a malignant behavior (Goodyear et al., 2009) .
Hypoxia is a stress for all mammalian cells and also a hallmark of aggressive solid tumor cells, wherein they acquire the capacity to survive and proliferate at conditions of low oxygen tensions (Brown and Wilson, 2004) . To cope with hypoxia, tumor cells use the adaptation mechanisms including stabilization and activation of hypoxia-inducible factors (HIFs), a family of transcription factors that have been identified as an important regulator of the cellular response to hypoxia (Semenza, 1998) . HIF-1 and HIF-2 are central components to set forth a range of cellular response to hypoxia and exist as a heterodimer of one oxygen-sensitive asubunit (HIF-1a and HIF-2a) and one b-subunit. On responding to hypoxia, each of these heterodimeric transcription factors translocates to the nucleus and activates transcription of genes involved in cellular and physiologic adaptation to low oxygen supply. A direct and important role of hypoxia in survival and progression of solid tumors is to stimulate tumor angiogenesis through HIF-induced expression of proangiogenic factors, such as VEGF (Ryan et al., 1998; Blancher et al., 2000) . HIF-1a and HIF-2a are not only regulated by hypoxia, and can be induced by non-hypoxic mechanisms involving growth factor-induced or oncogenic activation of signaling pathways (Semenza, 2003; Lo¨fstedt et al., 2007) . Several growth factors, including IGF-1 and EGF, have been reported to augment HIF1a level via induction of de novo protein synthesis or reduction of degradation of the protein (Zhong et al., 2000; Laughner et al., 2001; Fukuda et al., 2003) . A previous study showed that hypoxia and TGF-b1 can synergize in the induction of the promoter activity of VEGF (Sanchez-Elsner et al., 2001) .
In this study, we demonstrate that TGF-b1 activates VEGF transcription through the functional cooperation of Smad3 and HIF-2a under normoxic condition. Both HIF-1a and HIF-2a are induced by TGF-b1, but they have opposite roles in VEGF expression. TGF-b1 also enhances the stability of VEGF transcript via activation of an mRNA-stabilizing factor HuR. Together, our data show that TGF-b1 activates VEGF expression via multiple routes including Smad3, HIF-2a and HuR signaling, indicating that autocrine TGF-b1 production might contribute to angiogenesis under non-hypoxic conditions and thus provide a selective growth advantage for prostate tumor cells.
Results
VEGF expression is activated by tumor-producing TGF-b1 under non-hypoxic conditions A majority of malignant prostate tumors produce TGFb1 and express high level of VEGF in the absence of hypoxic stress. To explore the role for TGF-b1 in VEGF expression under normoxic conditions, we initially tested TGF-b1 effect on VEGF expression in DU145 prostate carcinoma cells. VEGF expression is strongly upregulated by TGF-b1 at both mRNA and protein levels in a time-and dose-dependent manner (Figures 1a  and b ). An increase of VEGF transcript level was clearly detectable as early as 3 h after treatment. Induction of two VEGF isoforms (VEGF 165 and VEGF 121 ) was verified by semiquantitative reverse transcription-PCR (RT-PCR). TGF-b1 induction of VEGF mRNA was markedly but not completely inhibited in the presence of actinomycin D, and the stability of VEGF mRNA was Waf1 was included as a positive control for TGF-b1 action and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous expression control. VEGF 165 and VEGF 121 transcripts were examined by semiquantitative RT-PCR using exon-specific primers. (Figures 2c and d ). In addition, mRNA level of HIF-1a and HIF-2a was substantially increased by TGF-b1 in a dose-dependent manner ( Figure 2e ). Similarly to protein induction, mRNA induction by TGF-b1 was transient, showing a maximum induction at 6 h after treatment ( Figure 2f ). These results indicate that TGF-b1 induces both HIF-1a and HIF-2a expression in prostate cancer cells under normoxic conditions.
Opposite roles of HIF-1a and HIF-2a in TGF-b1 induction of VEGF We next determined the role of HIF-1a and HIF-2a in TGF-b1-mediated VEGF expression. VEGF induction by TGF-b1 was suppressed by short-interfering RNA (siRNA)-mediated knockdown of HIF-2a but rather increased by HIF-1a knockdown (Figures 3a and b) . The opposite effects of HIF-1a and HIF-2a were also seen in siRNA dose-dependent fashion, whereas both HIF-1a and HIF-2a showed a stimulatory effect in hypoxiainduced VEGF expression (Figure 3c ). In both DU145 and PC3 cells, TGF-b1 led to about six-to eightfolds increase in VEGF 165 mRNA level at 9 h following treatment, but this induction was significantly suppressed by siHIF-2a transfection (Figure 3d ). Consistently, both intracellular and secreted VEGF protein levels were decreased by siHIF-2a but increased by siHIF-1a (Figures 3e and f), indicating that HIF-1a and HIF-2a have an opposite role in TGF-b1 regulation of VEGF in normoxia.
Our immunoblot assay has shown that HIF-2a level is increased earlier than HIF-1a level in response to TGF-b1 ( Figure 2a ). We thus evaluated whether time kinetics of the nuclear accumulation is associated with the differential role of HIF-1a and HIF-2a in VEGF induction. As shown in Figure 3g , the nuclear HIF-2a level showed a detectable increase after 2 h treatment and the highest level at 4 h, which is coincident with VEGF induction, whereas the nuclear HIF-1a level exhibited no visible increase up to 6 h and augmented after 8 h. The nuclear HIF-2a level showed a slow decrease after 6 h treatment but elevated level was detectable up to 12 h. This indicates that both HIF-1a and HIF-2a expression are induced, but their nuclear translocation is differentially regulated by TGF-b1 under normoxic conditions.
Smad3 signaling is required for TGF-b1 activation of VEGF transcription
To explore signaling pathways implicated in TGF-b1 induction of VEGF, we tested the involvement of the Smad pathway, a crucial mediator of TGF-b1 signaling. In response to TGF-b1, DU145 and PC3 cells showed increased phosphorylation of Smad 2 and Smad3, indicating that the TGF-b1-Smad signaling is intact in these cells (Figure 4a ). TGF-b1 induction of VEGF mRNA was significantly inhibited by transient expression of a dominant-negative (DN)-Smad3 or DNSmad4, whereas no detectable effect was observed by DN-Smad2 expression ( Figure 4b ). Consistently, secreted VEGF level was decreased by DN-Smad3 or DN-Smad4 in a dose-dependent manner ( Figure 4c ). Transient expression of a wild-type (WT)-Smad3 or WT-Smad4, but not WT-Smad2, led to a doseassociated induction of VEGF (Figure 4d ), indicating that TGF-b1 stimulation of VEGF occurs via the Smad3 pathway. It has been known that Smadindependent pathways has an important role in VEGF induction by TGF-b1 in concerted with Smad-dependent pathway (Benckert et al., 2003) . We also reported that TGF-b1 induces a synergistic collaboration of p38, NF-kB, c-Jun N-terminal kinase (JNK) and Ras signaling for interleukin-6 activation in DU145 and PC3 prostate cancer cells (Park et al., 2003) . We thus examined the possible involvement of other signaling pathways using various pharmacological inhibitors against MAPK/ERK kinase (MEK) (PD98059), p38 (SB202190), JNK (SP600125), PI3K (Wormanin and LY294002), NF-kB (BAY11-7082), Cox-2 (NS-398) and Src (PP2). TGF-b1 induction of VEGF was slightly inhibited by SP600125 and SB202190, but none of the inhibitors significantly affected VEGF induction at both mRNA and protein levels (Figures 4e and f), demonstrating that Smad3 signaling has a key role in TGF-b1 induction of VEGF.
Smad3 and HIF-2a cooperate for TGF-b1 activation of VEGF promoter
We performed a promoter assay to evaluate the role for Smad3, HIF-1a and HIF-2a in the regulation of VEGF transcription by TGF-b1 ( Figure 5a ). The reporter vector pVEGF/2361 containing two Smadbinding elements (SBE1 and SBE2) and one hypoxiaresponse element (HRE) exhibited a significant increase (B25-to 30-folds) of luciferase activity following TGFb1 treatment comparable with the positive control 3TPLuc, which carries the TGF-b1-responsive elements of the PAI-1 promoter ( Figure 5b ). Although pVEGF/ 1074, which has SBE1 deletion, showed a strong induction of luciferase activity, pVEGF/983 carrying deletion of both SBE1 and SBE2 displayed negligible response to TGF-b1 ( Figure 5c ). As predicted, pVEGF/ 961, which has deletion of SBEs and HRE, showed no promoter activity. The promoter response to TGF-b1 was markedly impaired when SBE2 or HRE was removed (1074-DSBE2 and 1074-DHRE, respectively, in Figure 5a ), indicating that the presence of both SBE2
TGF-b1 activation of VEGF in prostate cancer KS Chae et al and HRE are required for TGF-b1 activation of VEGF promoter. To further define the role of Smads and HIFs, we tested effect of its expression on promoter response to TGF-b1. As expected, the luciferase activity was markedly decreased and increased by DN-Smad3 and WT-Smad3, respectively, whereas DN-Smad2 and WT-Smad2 did not affect promoter response (Figure 5d) . Likewise, the promoter activity was strongly increased and decreased by siHIF-2a and WT-HIF-2a, respectively, further supporting that HIF-2a has a stimulatory role in VEGF induction by TGF-b1 (Figure 5e ). Consistent with the results from expression assays, TGF-b1 activation of VEGF promoter was further enhanced by HIF-1a knockdown, but decreased by WT-HIF-1a transfection, indicating that HIF-1a and HIF-2a have opposite roles in TGF-b1 activation of VEGF promoter. Collectively, these data demonstrate that SBE2 (À992 to À986) and HRE (À975 to À968) are essential for the Smad3-and HIF-2a-mediated induction of VEGF transcription by TGF-b1.
TGF-b1 activation of VEGF occurs through the functional collaboration of Smad3 and HIF-2a
To define the interplay of HIF-1a, HIF-2a and Smad3 on VEGF promoter, we carried out co-transfection assay. Compared with separate transfection, co-transfection of WT-HIF-2a and WT-Smad3 led to a synergistic elevation of promoter activity and this effect was seen in a dose-dependent fashion ( Figure 6a ). The synergistic effect of Smad3 and HIF-2a was blocked by WT-HIF-1a expression, whereas WT-Smad2 expression exerts only mild inhibitory effect (Figure 6b ), suggesting that Smad3 and HIF-2a collaborate on the promoter, and HIF-2a and HIF-1a might compete in an antagonistic mode. To determine whether Smad3 binds to the SBE2 site, and HIF-1a and HIF-2a influence this interaction, we performed an electrophoretic mobility shift analysis using a 25-bp synthetic oligonucleotide (WT-SBE2) containing the SBE2 site. One prominently shifted band was detected when the probe was incubated with nuclear extract purified from TGF-b1-treated cells, and the band was super shifted when Smad3 antibody was added (Figure 6c ). The specificity of this binding was confirmed by efficient competition with an excess of unlabeled WT-but not mutant-type competitor. Moreover, the Smad3 binding to SBE2 was disrupted when HIF-2a expression is knocked down, indicating that HIF-2a is required for the Smad3 binding to VEGF promoter (Figure 6d ). To elicit whether Smad3 indeed occupies the SBE2 site in living cells, we carried out a chromatin immunoprecipitation assay. A clear association was observed between Smad3 and the SBE2 site, when the cells were treated with TGF-b1, and this interaction was substantially attenuated by HIF-2a knockdown (Figure 6e ). Consistent with induction kinetics shown in Figure 1a , the Smad3 binding to the VEGF chromatin was detectable at 3 h, and remained up to 12 h after TGF-b1 treatment. We also found that both HIF-1a and HIF-2a bind to the HRE site in TGF-b1-treated cells (Figure 6f ). Interestingly, HIF-2a binding to the HRE site was detected at 3 h and reached to the maximum level at 6 h, whereas HIF-1a binding to the site was detectable only after 9 h treatment, indicating that HIF-2a and HIF-1a binding to the HRE site is highly associated with their nuclear levels and effects on VEGF promoter. Moreover, HIF-2a and HIF-1a interaction with the HRE site was increased by knockdown of HIF-1a and HIF-2a, respectively, suggesting that HIF-1a and HIF-2a might compete for binding to the HRE site (Figure 6g ). Taken together, our data show that TGF-b1 induction of VEGF transcription in normoxia is mediated by the functional collaboration of Smad3 and HIF-2a, whereas HIF-1a exerts an antagonizing effect on this cooperation.
TGF-b1 enhances the mRNA stability of VEGF via HuR activation Our expression study revealed that the mRNA stability of VEGF is also enhanced by TGF-b1 (Figures 1e and f). It has been known that HuR, a member of the Elav/ Hu family, which stabilizes target mRNAs and enhances their translation, binds VEGF mRNA through its AUrich elements located in the 3 0 untranslated region . We thus investigated whether HuR is involved in post-transcriptional regulation of VEGF by TGF-b1. As shown in Figure 7a , the induction of VEGF mRNA by TGF-b1 was attenuated by HuR knockdown, suggesting the involvement of HuR in TGF-b1-mediated VEGF induction. Moreover, the inhibitory effect of HuR knockdown was more apparent when higher doses of TGF-b1 were treated, suggesting that HuR activity might be upregulated by TGF-b1 in a dose-dependent manner (Figure 7b) . Likewise, TGF-b1 induction of secreted VEGF level was enhanced by WT-HuR transfection but reduced by HuR knockdown (Figure 7c ). HuR is predominantly localized in the nucleus, but it translocates to the cytoplasm in response to various stimuli and HuR subcellular localization is intimately linked to its function (Fan and Steitz, 1998; Tran et al., 2003) . Thus we examined whether TGF-b1 affects the cytoplasmic shuttling of HuR using the nuclear and cytoplasmic TGF-b1 activation of VEGF in prostate cancer KS Chae et al
Discussion
In this study, we show that HIF-1a and HIF-2a are activated by TGF-b1 in prostate cancer cells, but have opposite roles in VEGF expression under normoxic conditions. TGF-b1 induction of VEGF occurs in a Smad3-dependent manner and HIF-2a is required for the efficient interaction of Smad3 with the SBE2 site within the VEGF promoter. The synergistic cooperation of Smad3 and HIF-2a on the VEGF promoter is suppressed by HIF-1a. Both HIF-1a and HIF-2a are activated but show different time kinetics in nuclear translocation following TGF-b1 treatment. TGF-b1 also increases the mRNA stability of VEGF by the activation of a RNA-stabilizing factor HuR. Collectively, our data demonstrates that tumor-producing TGF-b1 activates VEGF at both transcription and posttranscriptional levels, and HIF-1a and HIF-2a have opposite roles in TGF-b1 regulation of VEGF under physiological oxygen tensions. TGF-b1 functions as a paracrine growth inhibitor in normal cells of the epithelial lineage by inducing cell cycle arrest and apoptosis, and many human cancers escape from TGF-b1-mediated growth suppression by mutational alterations of its receptors or Smads (Markowitz et al., 1995) . Unlikely normal epithelial cells, carcinoma cells produce active TGF-b1, which promotes tumor growth, migration and metastasis (Stearns et al., 1999; Zhu and Kyprianou, 2005; Lu et al., 2007; Pu et al., 2009) . In prostate tumorigenesis, TGF-b1 has biphasic functions, having a growth inhibitory effect at early stages, but at later stages enhancing the malignant properties of tumors. We previously showed that TGF-b1 function is mitogenically conversed in prostate carcinoma cells through the activation of the oncogenic Ras-MAPK signaling pathway (Park et al., 2000) . TGF-b1 is involved in blood vessel formation and one of its oncogenic functions is to promote tumor angiogenesis, which is associated with its ability to induce VEGF expression (Benckert et al., 2003; Sugano et al., 2003; Jeon et al., 2007) . A recent study demonstrated that TGF-b1 activates migration and invasion of intermediary basal epithelial cells of the prostate by induction of VEGF receptor type 3 and matrix metalloproteinase-2/9, indicating that TGF-b1 is involved in cell phenotype changes associated with transitions to a malignant behavior (Goodyear et al., 2009) . It was reported that Smad3 signaling activates VEGF transcription synergistically with augmented nuclear HIF-1a in hypoxia (SanchezElsner et al., 2001) . However, the molecular mechanism underlying VEGF induction by TGF-b1 under normal oxygen tensions has not been well defined. In this study, we found that Smad3 and HIF-2a have a key role in the transcriptional activation of VEGF by TGF-b1 in prostate carcinoma cells under normoxic conditions. TGF-b1 induction of VEGF was blocked by either DN-Smad3 or siHIF-2a, but not severely affected by inhibitors for MEK (PD98059), p38 (SB202190), JNK (SP600125) or PI3K (LY294002). Smad3 was identified to bind to the SBE2 site on the VEGF promoter, and this interaction was abolished by knockdown of HIF-2a expression. Likewise, VEGF induction was substantially enhanced by co-transfection of Smad3 and HIF-2a compared with transfection of either Smad3 or HIF-2a, indicating that HIF-2a cooperates with Smad3 in VEGF induction. These findings indicate that under physiological oxygen tensions, TGF-b1 stimulates VEGF transcription via HIF-2a rather than HIF-1a. Our data thus support that autocrine TGF-b1 production provides selective growth advantages for prostate tumors via transcriptional activation of tumor-promoting genes, such as VEGF, and also lead to the conjecture that VEGF induction counteracts the growth suppression function of TGF-b1 and thus contributes to the oncogenic conversion of TGF-b1 effect during tumor progression.
In normoxic state, HIF-1a is constitutively hydroxylated on specific proline residues, ubiquitinated by von Hippel Lindau protein, and degraded via proteosomal degradation pathway. Hypoxia impedes hydroxylation of HIF-1a, and eventually increases its protein level. In contrast to protein regulation, mRNA level of HIF-1a is generally not fluctuated by hypoxia or other growth factors except for some cases (Wang et al., 1995) . We observed that TGF-b1 upregulates protein expression of both HIF-1a and HIF-2a. In the presence of cyclohexamide, the degradation of HIF-1a and HIF-2a were suppressed by TGF-b1, indicating that TGF-b1 enhances the stability of both HIFa proteins. Consistent with our finding, a recent study demonstrated that TGFb1 selectively inhibits PHD2 expression, thereby impairs the HIF-1a degradation in normoxia (McMahon et al., 2006) . Interestingly, we also observed that mRNA expression of HIF-1a and HIF-2a is strongly induced by TGF-b1 in a dose-and time-dependent manner. A detectable increase of HIF-1a and HIF-2a transcript levels at 3 h after TGF-b1 treatment suggests that TGFb1 might directly activate the transcription of both genes in normoxia. We are exploring the molecular mechanism underlying TGF-b1 activation of HIF-a gene Despite of well-established HIF-1a role in tumor angiogenesis, several lines of evidences have supported differential or contrasting roles of HIF-1a and HIF-2a in VEGF expression (Lo¨fstedt et al., 2007; Noguera et al., 2009) . It was demonstrated that HIF-1a and HIF2a are regulated differently in a time-and oxygendependent fashion, and that hypoxia-induced VEGF expression is primarily driven by HIF-2a at prolonged hypoxia, whereas HIF-1a functions as a major VEGF inducer during acute hypoxic conditions (Uchida et al, 2004; Holmquist-Mengelbier et al., 2006; Helczynska et al., 2008) . HIF-2a expression in apparently well vascularized tumor areas where the cells are well oxygenized also suggest that HIF-2a can be active at physiologic oxygen tensions (Holmquist-Mengelbier et al., 2006; Pietras et al., 2008) . In addition, HIF-1a uniquely activates a few glycolytic enzymes, such as CA9 and BNip3, whereas HIF-2a essentially contributes to Oct-4, cyclin D1 and erythropoietin (EPO). Interestingly, in renal cell carcinoma cells, BNip3 was identified to be induced by either HIF-1a overexpression or HIF2a knockdown, demonstrating a contrasting role of both HIFa (Raval et al., 2005) . We found that HIF-1a and HIF-2a are induced by TGF-b1, but they have opposite roles in VEGF expression in prostate cancer (g) Competition of HIF-1a and HIF-2a for binding to the HRE site. DU145 cells were transfected with increasing doses of siHIF-2a or siHIF-a, and its influence on TGF-b1-mediated HIF-1a and HIF-2a binding to the HRE site was determined using chromatin immunoprecipitation assay. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
TGF-b1 activation of VEGF in prostate cancer KS Chae et al cells under normoxic conditions. Both mRNA and secreted protein levels of VEGF were elevated by siHIF1a but decreased by siHIF-2a in a dose-dependent manner. Likewise, the VEGF promoter response to TGF-b1 was down-and upregulated by ectopic expression of HIF-1a and HIF-2a, respectively. It is therefore, conceivable that HIF-2a might compete with HIF-1a in interplay with Smad3 on the VEGF promoter. This was supported by findings that Smad3 interaction with the SBE site on the VEGF promoter and its effect on the promoter activity are regulated positively and negatively by HIF-2a and HIF-1a, respectively. Our results also suggest that the opposite role of HIF-1a and HIF-2a might be associated with the different time kinetics of their nuclear translocation in response to TGF-b1. An obvious increase in nuclear HIF-2a was observed at 2 h following TGF-b1 treatment, which is coincides with VEGF mRNA induction, whereas HIF-1a translocation was detectable at 6 h after treatment. It is thus plausible that HIF-2a and HIF-1a have a reciprocal role in the TGF-b1 activation of VEGF in prostate cancer KS Chae et al Smad3 binding to the VEGF chromatin under normoxic conditions, exerting differential effect on VEGF promoter response to TGF-b1. It is becoming clear that HIF-2a has an important role in tumor development and progression. In xenograft models, overexpression of mutant HIF2a, which lost the von Hippel Lindau-binding activity, thus stabilized in nomorxia, was found to significantly promote the tumor growth, whereas the same kind mutant HIF-1a inhibited tumor growth, implying that HIF-2a but not HIF-1a is the critical target of von Hippel Lindau (Kondo et al., 2002; Maranchie et al., 2002) . Furthermore, high level of HIF-2a, but not HIF-1a, associates with distant metastasis, an immature stem-cell-like phenotype and poor outcome in some tumor types (Giatromanolaki et al., 2003; Yoshimura et al., 2004; Pietras et al., 2008) . HIF-2a is associated with breast-cancer-specific death and distant metastasis, whereas in neuroblastoma, HIF-1a correlates negatively to vascularization and shows an association with low tumor stage and favorable patient prognosis (Holmquist-Mengelbier et al., 2006; Helczynska et al., 2008; Noguera et al., 2009) . These findings raise an important issue that if these HIF-2a-positive cells indeed are tumor-initiating or stem cells, the capacity to produce VEGF and attract blood vessel formation under physiologic oxygen tensions might be crucial during an early phase of establishment of solid tumors (Noguera et al., 2009 ). These observations thus indicate that although expression of both HIF-1a and HIF-2a correlate with VEGF expression, they are not coherently regulated in vivo and associate with differently with patient outcome. In this context, our data suggest that TGF-b1 could enhance the invasive and metastatic potential of tumor cells through HIF-2a signaling, which has a wide range of oncogenic roles in prostate tumor progression. It was reported that HIF-1a level is higher in the intraepithelial neoplasia than the respective normal epithelium, stromal cells and benign prostate hyperplasia (Zhong et al., 2004) . However, a study using 149 radical prostatectomy specimens demonstrated that correlation of HIF-2a and VEGF is higher than that of HIF-1a and VEGF (Boddy et al, 2005) . These studies raise the possibility that HIF-1a upregulation is an early event in prostate tumorigenesis, but HIF-2a could be a dominant isoform in advanced prostate cancers. Considering that intracellular and serum TGF-b1 levels correlate with tumor malignancy in prostate cancer patients, our study suggests that HIF-2a might take the dominant role in the process of malignant tumor progression.
In this study, it was found that VEGF mRNA level is increased by TGF-b1 in the presence of actinomycin D, indicating that TGF-b1 also upregulated VEGF at the posttranscriptional level. Our study showed that HuR, a member of the Elav/Hu family that binds to target mRNA subsets bearing an AU-rich element, is activated by TGF-b1. HuR undergoes bidirectional nuclearcytoplasmic shuttling, with mRNA stabilizing activity presumed to occur in the cytoplasm, possibly in association with translational machinery (Fan and Steitz, 1998) . A growing body of evidence points to the key role of HuR in regulating various cellular responses, including cell proliferation, differentiation, inflammation, replicative senescence, immune cell activation and oncogenesis (Wang et al., 2001; Benjamin and Moroni, 2007) . HuR interacts with AU-rich elements of many angiogenic factors and immunomodulating cytokines, including VEGF, COX-2, c-Myc, interleukin-8, TGF-b and tumor necrosis factor-a (Wang et al., 2000; Dixon et al., 2001) . Accordingly, misregulated association of HuR with AU-rich elementcontaining transcripts could allow for enhanced expression of growth-related genes that can influence the neoplastic and angiogenic potential of cancer cells. HuR expression is aberrantly elevated in many human malignancies, including colon, brain and gastric cancers, and correlates with advancing stages of malignancy, supporting a role for HuR in tumorigenesis Kang et al., 2008) . We found that TGF-b1 stimulates the cytoplasmic translocation of HuR, and siRNA-mediated HuR knockdown leads to a detectable decrease in VEGF expression induced by TGF-b1, indicating that TGF-b1 induces VEGF expression at the post-transcriptional level via HuR activation. Recently, we reported that the expression and cytoplasmic HuR import of HuR is activated by the PI3K-Akt-NF-kB signaling in human gastric cancer (Kang et al., 2008) . Considering that Akt and NF-kB signaling are activated by TGF-b1 in many tumor cells, it will be valuable to examine to what extent HuR activation contributes to oncogenic effects exerted by autocrine TGF-b1 production in human tumors.
In conclusion, our study reveals that Smad3 and HIF-2a functionally cooperates and function synergistically in TGF-b1 induction of VEGF in prostate cancer cells under normoxic conditions. HIF-1a has an antagonistic function on the collaboration of Smad3 and HIF-2a on the VEGF promoter. TGF-b1 also increases VEGF mRNA stability by activation of a RNA-stabilizing factor HuR. Therefore, our study demonstrates that tumor-producing TGF-b1 activates VEGF at both transcription and post-transcriptional levels in prostate carcinoma cells under physiological oxygen tensions.
Materials and methods

Cell lines and reagents
Human prostate carcinoma cell lines DU145 and PC3 were maintained at 37 1C in RPMI-1640 medium supplemented with 10% fetal bovine serum (GIBCO BRL, Gaithersburg, MD, USA). Porcine TGF-b1 and anti-TGF-b1 neutralizing antibody were obtained from R&D Systems (Minneapolis, MN, USA). Cycloheximide (protein synthesis inhibitor), actinomycin D (RNA synthesis inhibitor), PD98059 (MEK1 inhibitor), SB202190 (p38 MAPK inhibitor), wortmannin and LY294002 (PI3K inhibitors), BAY 11-7082 (IKK-b inhibitor), NS-398 (COX-2 inhibitor), and PP2 (Src inhibitor) were purchased from Calbiochem (San Diego, CA, USA). Inhibitors were added to cultures 1 h before treatment of TGF-b1. Other reagents were obtained from Sigma (St Louis, MO, USA), if not indicated.
Semi-quantitative RT-PCR analysis
Total cellular RNA (1 mg) prepared by single-step method was reverse transcribed to complementary DNA using MoMuLV reverse transcriptase (GIBCO BRL) and random hexamer primers. For quantitative evaluation by RT-PCR, we initially performed the PCR reaction over a range of cycles (20-40 cycles), and 1:4 diluted complementary DNA (12.5 ng/50 ml PCR reaction) undergoing 24-36 cycles was observed to be within the logarithmic phase of amplification with all primers used for VEGF 121 , VEGF 165 , p21
Waf1
, HIF-1a, HIF-2a and an endogenous expression standard gene glyceraldehyde-3-phosphate dehydrogenase. Primer sequences are available upon request. The complementary DNA was subjected to 28-34 cycles of PCR at 95 1C (1 min), 58-60 1C (0.5 min) and 721C (1 min) in 1.5 mM MgCl 2 -containing reaction buffer (PCR buffer II, Perkin Elmer, Wellesley, MA, USA). RT-PCR products (10 ml) were resolved on 2% agarose gels. Quantitation of gene expression levels was achieved by densitometric scanning of the ethidium bromide-stained gels. Absolute area integrations of the bands representing each sample were then compared after adjustment for glyceraldehyde-3-phosphate dehydrogenase expression. Integration and analysis were performed using Molecular Analyst software program (Bio-Rad, Hercules, CA, USA).
Northern blotting analysis
Total RNA (5 mg) was separated on formaldehyde-agarose gel. RNA was transfered to nylon membrane using TurboBlotter (Schleicher & Schulell, Keene, NH, USA) and the membrane was baked in the CL-1000 UV crosslinker (UVP, Upland, CA, USA). Dioxigenin-labeled probes for VEGF 165 , p21
Waf1 and glyceraldehyde-3-phosphate dehydrogenase were prepared using PCR. Hybridization was conducted with Dig-labeled probes in the high SDS hybridization solution at 50 1C for 12 h. Detection was performed using DIG chemiluminescent detection kit (Roche, Basel, Switzerland) according to the manufacturer's protocol. The same blot was stripped and hybridized with Dig-labeled glyceraldehyde-3-phosphate dehydrogenase probe.
Enzyme-linked immunosorbent assay
The levels of VEGF protein in the conditioned media were measured using human VEGF enzyme-linked immunosorbent assay kit (R&D Systems), which is based on sandwich enzyme immunoassay technique. The supernatants of cultures from various conditions and VEGF standard provided by the manufacturer were assayed according to the manufacturer's instruction. The absorbance was determined using a microplate reader (Bio-Rad).
Immunoblotting analysis
Cells were lysed in a lysis buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM sodium fluoride, 2 mM sodium pyrophosphate, 1 mM sodium orthovanadate, protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride (PMSF). The cell lysate was clarified by centrifugation and 20-50 mg of total protein was supplemented with Laemmli buffer and loaded on an 8% SDS-polyacrylamide gel for electrophoresis. Immunoblotting analyses were performed using antibodies specific for VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), HIF-1/2a (Novus Biologicals, Littleton, CO, USA), pSmads (Millipore Corp, MA, USA), HuR (Santa Cruz Biotechnology) and Tubulin (Santa Cruz Biotechnology). Antibody binding was detected by enhanced chemiluminescence (Santa Cruz Biotechnology) using a secondary antibody conjugated to horseradish peroxidase. For reprobing with other antibodies, the membranes were incubated in a stripping buffer (0.2 M glycine pH 2.2, 0.1% SDS, 1% Tween-20) at 50 1C for 60 min.
siRNA, plasmid constructs and transfection siRNA duplex against HIF-1a (5 0 -CTGATGACCAGCA ACTTGA-3 0 ), HIF-2a (5 0 -CAGCATCTTTGATAGCAGT-3') and control siRNA duplex which served as negative control were synthesized by Invitrogen (Carlsbad, CA, USA). For transfection, 2 Â 10 5 cells were plated on 60-mm diameter dishes 24 h and incubated with a siRNA-oligofectamine mixture at 37 1C for 4 h. Fresh medium containing 1% fetal bovine serum was added and incubated for 20 h. Expression plasmids encoding DN-Smad2, DN-Smad3 and DN-Smad4 were described previously (Park et al., 2000) . Construction of WT-Smad2, WT-Smad3 and WT-Smad4 was described in a previous report (Park et al., 2003) . Transfection of expression plasmids was performed using Effectene (Qiagen, Hilden, Germany) according to the instruction of manufacturer. Briefly, 6 Â 10 4 cells were transfected with plasmidsEffectene mixture for 4 h. The transfected cells were incubated with RPMI-1640 medium with 1% serum for 20 h and then TGF-b1 was added for indicated duration. Detectable toxicity and apoptosis by reagent or vectors was rare. Each transfection experiment was carried out in triplicate. The transfection efficiency was monitored using a fluorescence microscopy for green florescence protein or CAT assay (Roche) according to the instruction of manufacturer.
Reporter constructs and luciferase assay
The reporter plasmid 3TP-Lux, which contains TGF-b1-responsive elements of the PAI-1 promoter was kindly provided by Dr Joan Massague (Memorial Sloan-Kettering Cancer Center, USA). The VEGF promoter regions were cloned into the pGL3-basic vector (Promega, Madison, WI, USA). Briefly, the pVEGF/2361 vector, which contains VEGF promoter region (nucleotides À2361 to þ 298), and other truncated or deletion constructs were amplified using PCR with primers which have linker sequences of KpnI and XhoI at 5 0 -and 3 0 -end, respectively, and amplicons were ligated to a pCR 2.1-TOPO vector (Invitrogen), and finally subcloned into pGL3 reporter vector. Cells (6 Â 10 4 cells/well) were transfected with 500 ng of the promoter constructs using Lipofectamine 2000 (Invitrogen). When the reporter vector was co-transfected with expression vectors and pCMVb-galactosidase vector, the whole amount of DNA in each transfection was adjusted to be same by using the empty expression vector. Luciferase activity was determined by luminometer (Junior LB 9509, Berthold Technologies, Bad Wildbad, Germany) and relative luciferase activity was calculated by normalization using b-galactosidase activity as an indicator of transfection efficiency. The mean and s.e.m. of luciferase acitivity were calculated and displayed as arbitrary unit.
Electrophoretic mobility shift and chromatin immunoprecipitation assay Synthetic oligonucleotides containing the SBE2 site (5 0 -GCG CCGACCGGAAGTCCCGCCTCTC-3 0 ) were biotin-labeled at its 3 0 -end. The annealed probes were incubated for 40 min with nuclear extract in a gel shift-binding buffer (Amersham Pharmacia Biotech. Piscataway, NJ, USA). Unlabeled probes were used 100-folds excess as a competitor. The reaction products were resolved using a 6% non-denaturing polyacryamide gel at 100 V for 2.5 h at room temperature and transfered onto nylon membrane. The probe-protein complex was detected using anti-streptavidin antibody-HRP conjugate. For supershift assay, 1 mg of anti-Smad3 antibody was added to the incubation solution. For chromatin immunoprecipitation, cells were incubated in 1% of formaldehyde solution for 20 min. The cells were lysed and the pellet was resuspended in nuclei lysis buffer and sonicated. Immunoprecipitation was performed with antibodies specific for Smad3 (Millipore Corp), HIF-1/2a (Novus Biologicals). PCR was performed using following primer pairs; HL2-5 (5 0 -CGAGGGCCGGAA CCCAGTTCGC-3 0 ) and HL-6 (5 0 -GCGGCTCCTCCTCAG CGCGCA-3 0 ).
Statistical analysis
Statistical analysis was conducted using a one-way analysis of variance and statistical values were presented as a mean± s.e.m. Throughout, Po0.05 was regarded as significant. All of the experiments were conducted in duplicate and repeated at least three times.
Abbreviations TGF-b1, transforming growth factor-b1; VEGF, vascular endothelial growth factor; HIF, hypoxia-inducible factor; NF-kB, nuclear factor-kB; PI3K, phosphoinositide-3-kinase; RT-PCR, reverse transcription-PCR; siRNA, short-interfering RNA.
